1. Home
  2. HTD vs CTMX Comparison

HTD vs CTMX Comparison

Compare HTD & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo John Hancock Tax Advantaged Dividend Income Fund of Beneficial Interest

HTD

John Hancock Tax Advantaged Dividend Income Fund of Beneficial Interest

HOLD

Current Price

$25.66

Market Cap

896.4M

Sector

Finance

ML Signal

HOLD

Logo CytomX Therapeutics Inc.

CTMX

CytomX Therapeutics Inc.

HOLD

Current Price

$4.39

Market Cap

977.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HTD
CTMX
Founded
N/A
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
896.4M
977.1M
IPO Year
2003
2015

Fundamental Metrics

Financial Performance
Metric
HTD
CTMX
Price
$25.66
$4.39
Analyst Decision
Strong Buy
Analyst Count
0
10
Target Price
N/A
$12.10
AVG Volume (30 Days)
54.2K
11.2M
Earning Date
01-01-0001
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$76,201,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$18.75
P/E Ratio
N/A
$22.58
Revenue Growth
N/A
N/A
52 Week Low
$21.47
$0.53
52 Week High
$26.12
$8.21

Technical Indicators

Market Signals
Indicator
HTD
CTMX
Relative Strength Index (RSI) 62.17 45.84
Support Level $24.28 $3.89
Resistance Level $25.65 $4.54
Average True Range (ATR) 0.35 0.29
MACD 0.11 -0.00
Stochastic Oscillator 94.70 41.14

Price Performance

Historical Comparison
HTD
CTMX

About HTD John Hancock Tax Advantaged Dividend Income Fund of Beneficial Interest

John Hancock Tax-advantaged Div Inc Fd is a closed-end, diversified management investment company. Its investment objective is to provide a high after-tax total return from dividend income and capital appreciation. The fund's portfolio composition consists of common stocks, preferred securities, corporate bonds, convertible bonds, and short-term investments. Its sector composition comprises utilities, financials, energy, communication services, materials, healthcare, real estate, consumer Staples, and short-term investments.

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Share on Social Networks: